When does weight loss stop on Mounjaro — and what does the evidence say?

What SURMOUNT-1 showed about the plateau

The most detailed picture we have comes from SURMOUNT-1, a 72-week randomised trial published in the New England Journal of Medicine involving 2,539 adults with obesity and no type 2 diabetes. Participants taking the 15mg dose lost an average of around 20–21% of their body weight over the course of the trial. The rate of loss was fastest in the first six months. By roughly weeks 36 to 40, most participants were approaching their lowest weight, and from there the curve flattened considerably rather than continuing to fall.

That flattening is not a sign the medicine has stopped working. At a biological level, tirzepatide suppresses appetite and slows gastric emptying by activating both GIP and GLP-1 receptors. As body weight falls, the body's energy needs decrease too, so the same degree of appetite reduction eventually produces a smaller additional deficit. The plateau is, in one sense, the body finding a new set point at that dose. Lower doses plateau earlier and at a higher weight; higher doses generally push the equilibrium lower, which is part of why prescribers titrate gradually.

For a fuller picture of what drives results during active treatment, the factors that affect weight loss on Mounjaro are worth reading alongside this.

Why your plateau might arrive earlier than the trial average

Trials measure averages. In practice, the timing of a plateau varies considerably from person to person, and several things bring it forward. Dose matters most: if 5mg or 7.5mg is the highest dose you tolerate without significant side effects, your plateau will likely arrive sooner and at a more modest weight reduction than the 15mg trial figures suggest. That is not a failure of the medicine or of you, tolerability varies, and a prescriber may explore whether a slower titration helps before concluding a higher dose is not right for you.

Lifestyle factors play a real role too. Mounjaro works alongside a reduced-calorie diet and increased physical activity, not instead of them. People who find their appetite suppression gradually becoming familiar (eating a little more over time without noticing) will see their progress slow faster. Strength-based activity helps preserve lean muscle mass as weight falls, which keeps metabolism from dropping as sharply. If you have questions about managing nausea or other side effects that affect tolerability, our page on using cyclizine alongside Mounjaro covers how some patients approach this. If you have questions about managing the plateau, our FAQs cover some of the most common concerns patients raise.

There is also a question of starting weight. Someone beginning treatment at a higher BMI has more absolute weight available to lose, so the percentage reduction may look similar to the trial while the absolute plateau takes longer to reach. The timeline for when loss typically begins is a useful companion to this question, because the full arc from first dose to plateau is longer than many people expect.

What happens at the plateau, and when to involve your prescriber

Reaching a plateau is a prompt for a clinical conversation, not a reason to stop treatment on your own. A prescriber will want to know whether you are on your highest tolerated dose, how your diet and activity levels look, whether the rate of loss has slowed or genuinely stopped, and for how long. In some cases a dose review is appropriate. In others, the plateau simply reflects that treatment is working as expected and that maintaining the new weight is itself a meaningful outcome.

The reasons weight loss can stall on Mounjaro go into specific scenarios in more detail. Cost is sometimes a factor in how long people stay on treatment, and if that is a consideration the cost of Mounjaro in the UK sets out what private treatment typically involves. One thing to be clear about: stopping Mounjaro once you have lost weight is a separate decision with its own evidence base, and the risk of regain after stopping is real and documented. That decision belongs with a prescriber, not a bathroom scale.

If you are thinking about starting Mounjaro or want a clinical view on where you are in treatment, our prescribers review consultations the same day, a real clinician reads your answers, not automated software. You can speak to our prescribers through a free consultation, with no subscription and no obligation to continue beyond each clinical review. Treatment, once approved, arrives in plain packaging via tracked DPD delivery the next working day.